This pilot study will investigate the use of PSMA-PET/MRI (Positron Emission Tomography/ Magnetic Resonance Imaging)to guide radiation treatment planning in patients with known or suspected locally metastatic prostate cancer at the time of diagnosis. Patients will undergo a single PSMA-PET/MRI (or PET/CT (Computed Tomography) in some circumstances) prior to initiation of treatment. Following development of a PSMA-PET guided radiation treatment plan, therapeutic radiation will be delivered per standard-of-care parameters and assessments of feasibility and tolerability will be performed.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
10
\[68Ga\]PSMA-PET/MRI or PET/CT
University of Alabama at Birmingham Medical Center
Birmingham, Alabama, United States
The Number of Patients Who Demonstrate Pelvic Lymph Node Metastases on PSMA-PET/MRI That Were Not Detected on MRI
Time frame: 1 scan
The Total Number of Pelvic Nodal Metastases Detected on PSMA-PET/MRI
Time frame: 1 scan
Number of Patients in Whom Dose-escalated Radiotherapy Can be Feasibly Delivered
Time frame: 1 simulation scan
Number of Patients Who Experience CTCAE (Common Terminology Criteria for Adverse Events) Grade 3-5 GI or GU Toxicities
Time frame: 18 months
The Total Number of Pelvic Nodal Metastases Detected on MRI
Time frame: 1 scan
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.